Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00004197

Public ClinicalTrials.gov record NCT00004197. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma

Study identification

NCT ID: NCT00004197
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: University of Nebraska; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Lymphoma

Interventions

cyclophosphamide Drug
doxorubicin hydrochloride Drug
keyhole limpet hemocyanin Biological
mitoxantrone hydrochloride Drug
prednisone Drug
sargramostim Biological
tumor cell-based vaccine therapy Biological
vincristine sulfate Drug

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years to 120 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 24, 1999
Primary completion: Dec 31, 2001
Completion: Nov 19, 2003
Last update posted: Sep 6, 2023

1999 – 2003

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Stanford University Medical Center	Stanford	California	94305-5408	—
University of Nebraska Medical Center	Omaha	Nebraska	68198-3330	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00004197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 6, 2023 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00004197 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →